Ralwel / iStockphoto.com
US-based Locus Biosciences has announced it will license its CRISPR-Cas3 technology to Janssen, a subsidiary of American pharmaceutical company Johnson & Johnson, in a deal worth a potential $818 million.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at email@example.com
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Locus Bioscences, Janssen, Johnson & Johnson, CRISPR-Cas3, CRISPR, bacteriophage, gene editing, genetics, patent licensing